


## Pozanicline dihydrochloride

## Chemical Properties

CAS No. :	161416-61-1
Formula:	C <sub>11</sub> H <sub>18</sub> Cl <sub>2</sub> N <sub>2</sub> O
Molecular Weight:	265.18
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Pozanicline dihydrochloride (ABT-089 dihydrochloride) is an orally bioavailable agonist of the nicotinic acetylcholine receptor (nAChR) with a $K_i$ of 16.7 nM.
Targets(IC50)	AChR
In vitro	Pozanicline is a partial agonist at $\alpha 4\beta 2$ nAChR. Moreover, one $\alpha 6\beta 2$ nAChR subtype is particularly sensitive to Pozanicline (EC <sub>50</sub> of 0.11 $\mu$ M)[2]. Pozanicline shows high selectivity for $\alpha 6\beta 2$ and $\alpha 4\alpha 5\beta 2$ nAChR subtypes[3].
In vivo	ABT-089, a partial agonist of $\alpha 4\beta 2^*$ , and ABT-107, an $\alpha 7$ nicotinic acetylcholine receptor agonist, for amelioration of cognitive deficits induced by withdrawal from chronic nicotine in mice. Mice underwent chronic nicotine administration (12.6 mg/kg/day or saline for 12 days), followed by 24 h of withdrawal. At the end of withdrawal, mice received 0.3 or 0.6 mg/kg ABT-089 or 0.3 mg/kg ABT-107 (doses were determined through initial dose-response experiments and prior studies) and were trained and tested for CFC. Nicotine withdrawal produced deficits in CFC that were reversed by acute ABT-089, but not ABT-107. Cued conditioning was not affected. Modulation of hippocampal learning and memory using ABT-089 may be an effective component of novel therapeutic strategies for nicotine addiction[3].

## Solubility Information

Solubility	H <sub>2</sub> O: 100 mg/mL (377.1 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	3.771 mL	18.8551 mL	37.7102 mL
5 mM	0.7542 mL	3.771 mL	7.542 mL
10 mM	0.3771 mL	1.8855 mL	3.771 mL
50 mM	0.0754 mL	0.3771 mL	0.7542 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Yildirim E, et al. ABT-089, but not ABT-107, ameliorates nicotine withdrawal-induced cognitive deficits in C57BL6/J mice. *Behav Pharmacol.* 2015 Apr;26(3):241-8.

Marks MJ, et al. Selectivity of ABT-089 for  $\alpha 4\beta 2$  and  $\alpha 6\beta 2$  nicotinic acetylcholine receptors in brain. *Biochem Pharmacol.* 2009 Oct 1;78(7):795-802.

Lin NH, et al. Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties. *J Med Chem.* 1997 Jan 31;40(3):385-90.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481